Bromfenac Sodium

Names

[ Name ]:
Bromfenac Sodium

[Synonym ]:
Bromfenacsodium
BENZENEACETIC ACID, 2-AMINO-3-(4-BROMOBENZOYL)-, MONOSODIUM SALT
BENZENEACETIC ACID,2-AMINO-3-(4-BROMOBENZOYL)-, SODIUM SALT (1:1)
bromfenac sodium salt
{2-amino-3-[(4-bromophényl)carbonyl]phényl}acétate de sodium
sodium {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetate
Sodium [2-amino-3-(4-bromobenzoyl)phenyl]acetate
Natrium-{2-amino-3-[(4-bromphenyl)carbonyl]phenyl}acetat
Bronuck
Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, sodium salt (1:1)
Bromfenac sodium

Biological Activity

[Description]:

Bromfenac sodium is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium is a brominated non-steroidal anti-inflammatory/analgesic drug (NSAID), and it is commonly used for the research of postoperative inflammation and pain following cataract surgery, and pseudophakic cystoid macular edema (CME)[1][2].

[Related Catalog]:

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Immunology/Inflammation >> COX

[Target]

COX-1:5.56 nM (IC50)

COX-2:7.45 nM (IC50)

[In Vitro]

Bromfenac (90 μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myoﬁbroblast activation in HConFs and HPFs[3]. Bromfenac (30-90 μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dose-dependent manner in HConFs and HPFs[3]. Bromfenac (30-90 μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs[3].

[In Vivo]

Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats[2]. Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats[2]. Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs[2]. Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats[2]. Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice[2]. Animal Model: Male Sprague-Dawley rats (150-250 g) are injected carrageenan[2] Dosage: 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200 μL) Administration: Rubbed onto the backs before 1-72 h of injected carrageenan Result: Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%. Applied 1 or 4 h prior to carrageenan challenge was active, but not when applied 24 h (or longer) prior to challenge at 0.2%.

[References]

[1]. Schechter BA, et, al. Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies. Clin Ophthalmol. 2019 Aug 1; 13:1439-1460.

[2]. Nolan JC, et, al. The topical anti-inflammatory and analgesic properties of bromfenac in rodents. Agents Actions. 1988 Aug; 25(1-2): 77-85.

[3]. Chen K, et, al. Bromfenac Inhibits TGF-β1-Induced Fibrotic Effects in Human Pterygium and Conjunctival Fibroblasts. Invest Ophthalmol Vis Sci. 2019 Mar 1; 60(4): 1156-1164.

Chemical & Physical Properties

[ Boiling Point ]:
562.2ºC at 760 mmHg

[ Melting Point ]:
285ºC

[ Molecular Formula ]:
C₁₅H₁₁BrNNaO₃

[ Molecular Weight ]:
356.147

[ Flash Point ]:
293.8ºC

[ Exact Mass ]:
354.981995

[ PSA ]:
83.22000

[ LogP ]:
2.13590

[ Appearance of Characters ]:
faint yellow to dark yellow

[ Vapour Pressure ]:
1.77E-13mmHg at 25°C

[ Storage condition ]:
2-8°C

[ Water Solubility ]:
H2O: ≥5mg/mL

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS09

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H400

[ Precautionary Statements ]:
P273

[ Hazard Codes ]:
N

[ Risk Phrases ]:
50

[ Safety Phrases ]:
61

[ RIDADR ]:
UN 3077 9 / PGIII

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Articles

Multiparametric assay using HepaRG cells for predicting drug-induced liver injury.

Toxicol. Lett. 236 , 16-24, (2015)

The utility of HepaRG cells as an in vitro cell-based assay system for assessing drug-induced liver injury (DILI) risk was investigated. Seventeen DILI-positive and 15 DILI-negative drugs were selecte...

Efficacy of ophthalmic nonsteroidal antiinflammatory drugs in suppressing anterior capsule contraction and secondary posterior capsule opacification.

J. Cataract Refract. Surg. 35(9) , 1614-8, (2009)

To evaluate the efficacy of ophthalmic nonsteroidal and steroidal antiinflammatory drugs in preventing anterior capsule contraction and secondary posterior capsule opacification (PCO) using an experim...

Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model.

Curr. Eye Res. 34(3) , 171-6, (2009)

To examine the effects of COX inhibitors on suppressing HSV-1 reactivation in a mouse model.BALB/c mice were latently infected with HSV-1 and treated by 0.1% bromfenac Na eye drops, 0.1% pranoprofen e...

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.